Inventor · disambiguated record
Zhen Li
Also filed as: LI ZHEN · LI ZHEN LIN
36 granted patents·38 pending applications·169 citations·filing 1996–2025
97Inventor score
Files withARROWHEAD PHARMACEUTICALS INC45ADARX PHARMACEUTICALS INC8MERCK & CO INC4NANJING ZAIMING PHARMACEUTICAL CO LTD2PASTEUR INSTITUT2
Top patents by PatentIndex Score
74 records- 0196US10450565B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Oct 22, 2019·15 cites·39 claims
- 0295US11884920B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Jan 30, 2024·2 cites·21 claims
- 0395US9932586B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Apr 3, 2018·9 cites·39 claims
- 0494US11517584B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 6, 2022·2 cites·58 claims
- 0594US11214801B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·3 cites·30 claims
- 0693US10662427B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 26, 2020·6 cites·39 claims
- 0793US10597657B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 24, 2020·6 cites·51 claims
- 0892US11590156B2RNAi agents for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 28, 2023·2 cites·37 claims
- 0992US11203756B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Dec 21, 2021·5 cites·25 claims
- 1092US10780108B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Sep 22, 2020·5 cites·67 claims
- 1192US10294474B2Targeting ligandsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted May 21, 2019·15 cites·50 claims
- 1292US10246709B2Targeting ligands for therapeutic compoundsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·10 cites·27 claims
- 1390US7351725B2N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonistsMERCK & CO INC·Filed 2003·Granted Apr 1, 2008·40 cites·10 claims
- 1489US11174481B2Targeting ligandsARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Nov 16, 2021·3 cites·4 claims
- 1587US2025243485A1Targeting Ligands For Therapeutic CompoundsARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1686US11180529B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Nov 23, 2021·3 cites·18 claims
- 1786US2025115907A1Compositions and methods for inhibiting gene expression of lpaARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1885US12365899B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jul 22, 2025·0 cites·22 claims
- 1984US2024141351A1Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2083US10995335B2RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 4, 2021·3 cites·19 claims
- 2182US11597701B2Integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 7, 2023·2 cites·24 claims
- 2282US7199142B21-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonistsMERCK & CO INC·Filed 2003·Granted Apr 3, 2007·21 cites·12 claims
- 2381US10590416B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·1 cites·52 claims
- 2480US2023355651A1Rnai agents for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2577US2022064646A1RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2676US12116573B2Targeting ligands for therapeutic compoundsARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Oct 15, 2024·0 cites·3 claims
- 2776US11492624B2RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1ARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Nov 8, 2022·1 cites·21 claims
- 2871US2022090077A1RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2969US12173086B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 24, 2024·0 cites·15 claims
- 3069US11214802B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·0 cites·42 claims
- 3169US2020263179A1Compositions and methods for inhibiting gene expression of lpaARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3267US2024076270A1Integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3367US2022033817A1Targeting LigandsARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3466US12441756B25′-cyclo-phosphonate modified nucleotidesARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Oct 14, 2025·0 cites·16 claims
- 3566US2025092072A1Trialkyne Linking Agents and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3664US2019255091A1RNAi AGENTS FOR HEPATITIS B VIRUS INFECTIONARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3763US2025388900A1Compositions and Methods for Inhibition of Factor XII Gene ExpressionARROWHEAD PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3863US2025311705A1Method of genetic manipulation of neural cells in gyrencephalic fetal brain and uses thereofCHILDRENS NAT MEDICAL CT·Filed 2025·Application pending·0 cites
- 3962US2019211333A1Targeting Ligands For Therapeutic CompoundsARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4062US2025073256A1Prekallikrein-modulating compositions and methods of use thereofADARX PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4161US12042509B2Prekallikrein-modulating compositions and methods of use thereofADARX PHARMACEUTICALS INC·Filed 2022·Granted Jul 23, 2024·0 cites·36 claims
- 4261US2021238602A1RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of UseARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4361US2024041913A1Angiotensinogen-modulating compositions and methods of use thereofADARX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4461US2025000941A1Recombinant Protein For Inducing Cytoplasmic Vacuolization Cell Death And Use ThereofUNIV SHANDONG·Filed 2024·Application pending·0 cites
- 4560US2023013022A1RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4659US11078227B25′-cyclo-phosphonate modified nucleotidesARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Aug 3, 2021·0 cites·19 claims
- 4759US2025122221A1Six-membered cyclothiazole compound and use thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 4859US2025304717A1Camptothecin derivative and ligand-drug conjugateHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 4958US2022152079A1Methods For The Treatment Of APOC3-Related Diseases And DisordersARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 5056US2025312367A1Oligonucleotides having a synthetic backbone and synthesis thereofADARX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Zhen Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →